Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA's 'Skeletal' Cybersecurity Team: Schwartz Makes Case For More Cybersecurity Resources

Executive Summary

In an exclusive podcast interview with Medtech Insight, Suzanne Schwartz, the top US FDA official on medical device cybersecurity issues, says the agency is working with a lean but effective team and will need more funding as more connected devices come to market.

You may also be interested in...



Hacking The Budget: US FDA Asks For More Money To Tackle Cybersecurity

The agency is again trying to get extra funding in its budget for a cybersecurity information sharing portal in its proposed fiscal year 2020 budget. FDA says the approach will not only help mitigate cybersecurity risks in near-real time, but also help speed up device reviews.

US FDA Pushes Further On Cybersecurity Efforts Despite Limited Resources

US FDA unveiled multiple cybersecurity-related initiatives, including two memoranda of understandings to launch information sharing organizations and playbook for health-care delivery organizations. The agency is continuing a multi-front attack in the area, despite limited resources.

New Safety Framework Mixes Current Efforts, New Investments At US FDA

In a new "action plan," FDA is stitching together a plethora of ongoing and proposed initiatives to help spur product safety and quality efforts through increased regulatory authority and more incentives for device-makers.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT123391

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel